SG

Steve Gullans

CEO at Gemphire Therapeutics

Steve Gullans is the CEO of Gemphire Therapeutics. Steve has previously served as an advisor to Partners Innovation at Mass General Brigham, co-founder and managing director of Excel Venture Management, and advisor to the commercialization advisory board for the Global Cardiovascular Innovations Center at Cleveland Clinic.

Gullans has also served as president and CEO of Gemphire Therapeutics from May 2018 to December 2019. Gemphire was a clinical stage public company listed on the Nasdaq that was developing a treatment for cardiometabolic diseases. The company completed 3 successful Phase 2 trials and signed a partnership with a Chinese pharma. Gemphire merged with NeuroBo Pharmaceuticals in December 2019.

Steve Gullans completed their undergraduate studies at Union College, where they earned a Bachelor of Science degree. Steve then attended Duke University, where they earned a Doctor of Philosophy in physiology. After completing their PhD, Steve Gullans undertook post-doctoral research in physiology at Yale University School of Medicine.

Some individuals on their team include Seth Reno - Chief Commercial Officer, Charles Bisgaier - Chief Scientific Officer and Co-Founder.

Timeline

  • CEO

    Current role

View in org chart